Sunday, June 10, 2018 12:20:14 AM
June 08, 2018 05:02 PM Eastern Daylight Time
LOS ANGELES--(BUSINESS WIRE)--MedMen Enterprises Inc. (CSE: MMEN) (“MedMen”), the country’s leading cultivator, producer and retailer of state-sanctioned cannabis, announced today that the grant units for its co-founders under its long-term incentive plan (the “LTIP”) will now vest upon achievement of certain share price goals.
Co-founder and CEO Adam Bierman and Co-founder and President Andrew Modlin will receive their LTIP units of MM Enterprises USA LLC according to the following schedule. One third of the total units will vest when the price of MedMen’s Subordinated Voting Shares reaches CA$ 10 in the open market, another third will vest when the share price reaches CA$ 15 and the final third when the share price reaches CA$ 20. The price will be determined as a 5-day VWAP in any exchange where MedMen shares are traded.
This modification to the grants under the LTIP was made to provide greater economic alignment with MedMen’s shareholders.
About MedMen
MedMen Enterprises is the preeminent cannabis company in the United States with multiple assets and operations in California, Nevada and New York, which combined account for nearly half of North America’s addressable legal market. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is one of the most well recognized cannabis brands in the world today. Headquartered in Los Angeles, MedMen employs 800 workers across the United States. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society’s relationship with cannabis. MedMen supports sensible, clear and just drug laws. The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates. For more information, visit http://www.medmen.com or follow us on Facebook, Twitter or Instagram.
Source: MedMen Enterprises
Contacts
Media Contact:
Daniel Yi
Senior Vice President of Corporate Communications, MedMen Enterprises
daniel@medmen.com
or
Investor Relations Contact:
Quote:
"Hello MEDMEN,
I was super excited about Medmen trading publicly in CA and eventually with a U.S. foreign issue OTC ticker. I opened a couple discussion boards on Investors HUB and was truly excited about investing in stock in this company.
I live in the U.S.
And then came the press about the use of the public company initial proceeds and the percentage of the company that individual investors would hold when investing in company shares.
The numbers here are rough and approximate.
Of the $100,000,000 in proceeds, approx half of that went directly into the pockets of the principals.
Roughly 7 percent of the company is owned by investors of company stock.
These numbers are ghastly and I declined to invest in Medmen.
How is the company going to repair its tarnished image with the investment community?"
JohnCM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM